Mr John Dallow
I have been working on the development and surveillance of anti-infectives in industry for over 15 years. I started my career in post-marketing, resistance surveillance of respiratory pathogens across the globe, studying the epidemiological and usage considerations of new and established anti-infectives. More recently, my focus has moved to early drug discovery, helping characterise novel antimicrobial agents and identify targets using genetic engineering and interference in whole cell assays. In recent months, my work has also focussed on combating Covid-19 by disrupting interactions reported between the SARS-CoV-2 virus and human cells.
My research has focused on harnessing bacterial genetics to identify targets of antimicrobial compounds and to assess drug pharmacology from a microbiological perspective. I have worked on assessing how different PK/PD parameters work in in vitro models to drive bacterial kill, optimising dosing strategies for antimicrobial therapy.